Literature DB >> 21294789

The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk.

Yasuhito Nannya1, Keisuke Kataoka, Akira Hangaishi, Yoichi Imai, Tsuyoshi Takahashi, Mineo Kurokawa.   

Abstract

Optimal donor selection is one of the key factors to enhance the success rate of allogeneic hematopoietic stem cell transplantation (HSCT). The effect of sex mismatch, especially the effect of Y chromosome mismatch in graft-versus-host disease (GVHD) direction (female donors to male recipients: denoted as FtoM mismatch) on overall survival (OS) has been controversial and not examined out of the patient population in Western countries. We retrospectively analyzed 225 cases of allogeneic HSCT and showed that FtoM mismatch confers a highly significant impact on OS (P < 0.005) in Japanese population. We demonstrated that this effect depends on the disease risk; for standard risk cases, this effect was significantly associated with poor outcome (for OS, P = 0.021), while for high risk cases, it had no effect on the results (for OS, P = 0.26). We further showed that FtoM mismatch was associated with nonrelapse mortality (P = 0.019) and most of them were GVHD-related in standard risk cases. In conclusion, FtoM mismatch has a significant impact on transplant outcome, especially in standard risk cases.
© 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation.

Entities:  

Mesh:

Year:  2011        PMID: 21294789     DOI: 10.1111/j.1432-2277.2011.01229.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  12 in total

1.  BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient.

Authors:  Hideki Nakasone; Koji Kawamura; Kimikazu Yakushijin; Akihito Shinohara; Masatsugu Tanaka; Kazuteru Ohashi; Shuichi Ota; Naoyuki Uchida; Takahiro Fukuda; Hirohisa Nakamae; Ken-Ichi Matsuoka; Junya Kanda; Tatsuo Ichinohe; Yoshiko Atsuta; Yoshihiro Inamoto; Sachiko Seo; Fumihiko Kimura; Masao Ogata
Journal:  Blood Adv       Date:  2019-06-11

2.  Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia.

Authors:  Yasushi Onishi; Takehiko Mori; Hirohito Yamazaki; Katsuto Takenaka; Hiroki Yamaguchi; Naoki Shingai; Yukiyasu Ozawa; Hiroatsu Iida; Shuichi Ota; Naoyuki Uchida; Toshihiro Miyamoto; Yuta Katayama; Jun Kato; Satoshi Yoshioka; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta
Journal:  Ann Hematol       Date:  2020-10-09       Impact factor: 3.673

Review 3.  Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation.

Authors:  Yun R Li; John E Levine; Hakon Hakonarson; Brendan J Keating
Journal:  Eur J Hum Genet       Date:  2013-11-20       Impact factor: 4.246

4.  Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.

Authors:  Hideki Nakasone; Mats Remberger; Lu Tian; Petter Brodin; Bita Sahaf; Fang Wu; Jonas Mattsson; Robert Lowsky; Robert Negrin; David B Miklos; Everett Meyer
Journal:  Haematologica       Date:  2015-08-06       Impact factor: 9.941

5.  Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease.

Authors:  Rena C Zuo; Haley B Naik; Seth M Steinberg; Kristin Baird; Sandra A Mitchell; Zoya Kuzmina; Steven Z Pavletic; Edward W Cowen
Journal:  JAMA Dermatol       Date:  2015-01       Impact factor: 10.282

6.  Salvaged allogeneic hematopoietic stem cell transplantation for pediatric chemotherapy refractory acute leukemia.

Authors:  Jingbo Wang; Lei Yuan; Haoyu Cheng; Xinhong Fei; Yumin Yin; Jiangying Gu; Song Xue; Junbao He; Fan Yang; Xiaocan Wang; Yixin Yang; Weijie Zhang
Journal:  Oncotarget       Date:  2017-12-01

7.  Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT.

Authors:  Simona Piemontese; Ariane Boumendil; Myriam Labopin; Christoph Schmid; Fabio Ciceri; William Arcese; Yener Koc; Zafar Gulbas; Johanna Tischer; Benedetto Bruno; Depei Wu; Didier Blaise; Dietrich Beelen; Giuseppe Irrera; Annalisa Ruggeri; Mohamed Houhou; Mohamad Mohty; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2019-07-04       Impact factor: 17.388

8.  Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Dalila Salvatore; Myriam Labopin; Annalisa Ruggeri; Giorgia Battipaglia; Ardeshir Ghavamzadeh; Fabio Ciceri; Didier Blaise; William Arcese; Gerard Sociè; Jean Henri Bourhis; Maria Teresa Van Lint; Benedetto Bruno; Anne Huynh; Stella Santarone; Eric Deconinck; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

9.  Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure.

Authors:  Natasha Ali; Hayat Ullah; Mohammad Usman Shaikh; Salman Naseem Adil
Journal:  Int J Hematol Oncol       Date:  2019-12-18

10.  Cardiopulmonary performance in allogeneic hematopoietic cell transplantation recipients-evaluation of pre-transplant risk assessments.

Authors:  Antonia Pahl; Sarah Waibel; Anja Wehrle; Gabriele Ihorst; Albert Gollhofer; Hartmut Bertz
Journal:  Bone Marrow Transplant       Date:  2021-01-06       Impact factor: 5.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.